Emmenology (MENOPAUSE & PERIMENOPAUSE) Part 2 with Monica Christmas, Mary Claire Haver and Sarah Witkowski

Episode Summary

Executive Summary: Part two of this menopause deep dive focuses on practical management: hormone therapy choices, mental health, testosterone, vaginal and skin effects, clot risk, bone and cardiovascular health, and options for people who can’t or shouldn’t use hormones. Experts emphasize nuanced, individualized care, the safety advantages of transdermal estrogen, the importance of progesterone when a uterus is present, and exercise/nutrition as key tools alongside medical treatment.

Main Topics: Hormone therapy basics and formulation choices (Priority: 5/5): Drs. Haver and Christmas explain how menopausal hormone therapy differs from birth control, when estrogen is used, and why progesterone is required for people with a uterus. They discuss oral vs transdermal routes, vaginal local therapy, and why compounded or pellet approaches are often discouraged. Mental health in perimenopause (Priority: 5/5): The episode highlights anxiety, depression, irritability, and mood instability as common perimenopausal symptoms. Estrogen therapy is presented as often more effective than SSRIs for new-onset menopausal mood symptoms, though antidepressants and therapy still have a role. Testosterone for libido, muscle, and bone (Priority: 4/5): Testosterone is framed as an underused, off-label but evidence-supported option for some postmenopausal people with hypoactive sexual desire disorder and for maintaining muscle, bone, energy, and mood. The speakers caution against pellets and unregulated dosing. Genitourinary syndrome, vaginal estrogen, and local symptoms (Priority: 5/5): The conversation covers vaginal dryness, painful sex, recurrent UTIs, vulvar/labial changes, odor changes, and ear itching as estrogen-related issues. Vaginal estrogen is described as a long-term, local treatment that can protect urinary and vaginal tissues. Bone health, muscle, protein, and exercise (Priority: 5/5): Dr. Witkowski explains that estrogen decline accelerates bone loss and that resistance/impact training, adequate protein, calcium from food, and vitamin D are central to preventing osteoporosis and frailty. Building muscle is presented as crucial for independence. Cardiovascular risk and hot flashes (Priority: 4/5): The episode links menopause to increased cardiovascular risk, altered cholesterol, and heart rate variability changes. Physical activity is emphasized as a way to reduce cardiovascular risk and may blunt the relationship between hot flashes and heart disease. Non-hormonal and special-population care (Priority: 4/5): For people who cannot use hormones, the show reviews NK3 receptor antagonists, some antidepressants, gabapentin, SNRIs, and support for cancer survivors and trans/non-binary people. The episode stresses individualized care and acknowledges racial and gender disparities in treatment access.

Key Arguments: Menopausal treatment should be individualized; there is no one-size-fits-all plan. If a person has a uterus and uses estrogen, progesterone/progestogen is necessary to protect the endometrium. Transdermal estrogen is safer than oral estrogen for clot risk because it avoids first-pass liver effects. Estrogen therapy can be highly effective for perimenopausal anxiety and depression, sometimes more so than SSRIs for new-onset symptoms. Testosterone can improve libido, energy, muscle, and bone when used carefully at physiologic doses, but pellets and excess dosing are risky. Vaginal estrogen is a cornerstone treatment for GSM, recurrent UTIs, dryness, and vulvar tissue changes. Bone loss accelerates around the menopause transition, so resistance training and impact exercise matter before and after menopause. Cardiovascular health should be monitored through blood pressure, cholesterol, glucose, sleep, and activity because menopausal change can worsen risk. Not all menopausal symptoms require hormones; NK3 antagonists and certain antidepressants can be effective alternatives. Healthcare disparities mean Black women and trans/non-binary people are often underserved or undertreated in menopause care.

Data Points: Study participants in WHI: ~16,000 - Women aged 50-79 in the Women's Health Initiative trial that influenced hormone-therapy fears Age in WHI trial: Average 63 - Hormones in WHI were started later than typical perimenopause symptom onset HRT use after WHI: Dropped by 50% - Hormone therapy utilization fell after the 2002 WHI report Perimenopause duration: Up to a decade - Mood symptoms and hormonal fluctuation can persist for many years Hot flashes prevalence: About 80% - Vasomotor symptoms affect most women during the menopause transition Older adults with inadequate protein intake: Up to 46% - Harvard Health summary cited to support protein adequacy concerns Protein target: 0.5–0.75 g per lb body weight/day - Suggested intake to support muscle and tissue repair in older adults 65+ hip fracture mortality: Over 30% die within 1 year - The episode cites a 2025 orthopedic study on traumatic hip fractures Hip fracture age distribution: Up to 96% age 65+ - Most hip fractures occur in older adults Vitamin D deficiency among postmenopausal people: Up to 80% - Frontiers in Physiology paper cited for bone-health relevance Exercise frequency recommendation: At least 2 days/week - Strength training recommended for bone and muscle health LLLT hair-loss trial: 50 volunteers - 2014 scalp laser/LED study in women with androgenic alopecia LLLT duration: Every other day for 25 minutes for 4 months - Protocol used in the hair-growth device study Topical estrogen skin trial: 90 participants; 70% hydration improvement - Double-blind placebo-controlled study referenced for estriol/estrogen skin effects Depression-score correlates: Younger age, lower education, smoking - 2024 menopause-clinic study associating these factors with higher depression scores Transdermal vs oral clot risk: No extra clot/stroke risk for transdermal estrogen - 2025 meta-analysis and earlier hematology reviews cited NK3 antagonist symptom benefit: Hot flashes/night sweats reduced by ~70% - Non-hormonal treatment discussed for vasomotor symptoms

Pivotal Quotes: "If you have a uterus, you cannot take estrogen without progesterone, okay?" — Dr. Mary Claire Haver: Explaining the need for endometrial protection with menopausal hormone therapy "The best physical activity somebody can do is the kind that they're going to stick with." — Dr. Sarah Witkowski: Advising on sustainable exercise for bone, cardiovascular, and mood benefits "Transdermal estrogen ... does not increase clotting or stroke risk" — Narration/summary of cited research: Discussing why patches, gels, creams, and rings are preferred over oral estrogen for many patients

Implications: Listeners should expect more personalized menopause care: transdermal estrogen, progesterone pairing, local vaginal therapy, resistance training, protein, and cardiovascular screening are key. The episode also pushes clinicians to close gaps in menopause education and address racial, gender, and access inequities.